Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine

Summary

This is an open label booster vaccine follow-up study. Participants who had received a primary course of GBS-NN/NN2 or placebo in Study MVX0002 will be invited to return to receive a booster dose (or first dose in the case of placebo or vaccine naïve participants) 1 to 5 years after the completion of the primary course of vaccination. All participants will receive a single dose of GBS-NN/NN2 containing 50μg of each fusion protein.

Timeline

Start

2021-08-17

Primary completion

2022-08-05

Completion

2022-08-05

Drugs

Indications